A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol

NCT01817452 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

220

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Paclitaxel

Sponsor

West German Study Group

Collaborators

[object Object]